A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA)

Jehan Mohammad Ezzat Hamed; Rabab Mohamed Mohamed

doi:doi:10.11648/j.ijacm.20221001.13

| Peer-Reviewed

A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA)

Jehan Mohammad Ezzat Hamed, Rabab Mohamed Mohamed

Published in International Journal of Anesthesia and Clinical Medicine (Volume 10, Issue 1)

Received: 23 March 2022 Accepted: 9 April 2022 Published: 14 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Total hip arthroplasty (THA) faces the hazard of surgical blood loss and significant invisible blood loss due to bleeding into tissue and hemolysis. Tranexamic acid (TXA) and fibrinogen are important agents among a diversity of intraoperative blood management protocols. During the coagulation cascade, thrombin enhances fibrinogen and hastens fibrin polymerization forming an intense network important in clot formation. Our study included sixty male patients that were randomized into two groups; patients receiving 15 mg/kg TXA given as a single slow intravenous bolus injection 15 minutes before incision were placed in (group 1). Patients receiving 30 mg/kg fibrinogen concentrate administered post induction of general anesthesia were placed in (group 2). Intraoperative (IO) mean heart rate (HR) and mean arterial pressure (MAP) showed no significant differences. There was a significant decrease in IO blood loss in fibrinogen (723.03. ± 117.69) group compared to TXA (879.30 ± 168.54) (p=0.001), with significant (P=0.010) differences in the amount of transfused packed RBCs (IQR:1-2). Field visibility also improved significantly (p=0. 017) in fibrinogen group. The amounts of Lactated Ringer’s (LR) solution infused during surgery were not significantly different while a significant (p=0.037) decrease in the additional amount of hydroxyethyl starch (HES) solution infused in patients with fibrinogen (211.87 ± 32.30) over TXA (250.63 ± 43.65) was noted. In conclusion, administration of fibrinogen concentrate before procedure in patients undergoing THA reduces blood loss. Consequently, this therapeutic process has the potential to change the treatment model for perioperative hemorrhage in patients with potentially life-threatening coagulopathy.

Published in	International Journal of Anesthesia and Clinical Medicine (Volume 10, Issue 1)
DOI	10.11648/j.ijacm.20221001.13
Page(s)	16-23
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Tranexamic Acid, Fibrinogen Concentrate, Total Hip Arthroplasty, General Anesthesia

References

[1]	Knight SR, Aujla R, Biswas SP. Total hip arthroplasty—over 100 years of operative history. Orthop Rev 2011; 3: 2.
[2]	Liu X, Zhang X, Chen Y, et al. Hidden blood loss after total hip arthroplasty. J Arthroplasty 2011; 26: 1100–5.
[3]	Green WS, Toy P, Bozic KJ. Cost minimization analysis of preoperative erythropoietin vs autologous and allogeneic blood donation in total joint arthroplasty. J Arthroplasty 2010; 25: 93–6.
[4]	Tengborn L, Blombäck M, Berntorp E. Tranexamic acid—an old drug still going strong and making a revival. Thromb Res 2015; 135: 231–42.
[5]	Yi Z, Bin S, Jing Y, et al. Tranexamic acid administration in primary total hip arthroplasty: a randomized controlled trial of intravenous combined with topical versus single-dose intravenous administration. J Bone Joint Surg Am 2016; 98: 983–91.
[6]	Francis JL. Hemostasis and thrombosis: basic principles and clinical practice. Blood Coagulation Fibrinol. 1994; 5 (5): 855.
[7]	Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, et al. Prevalence and impact of abnormal ROTEM (R) assays in severe blunt trauma: results of the ’Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study’. Br J Anaesth. 2011; 107 (3): 378-87. https://doi.org/10.1093/bja/aer158
[8]	Karlsson M, Ternström L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. Thromb Haemost. 2009; 102 (07): 1137–1144.
[9]	Park JH, Kim HS, Yoo JH, et al. Perioperative blood loss in bipolar hemiarthroplasty for femoral neck fracture: analysis of risk factors. Hip Pelvis. 2013; 25: 110–114.
[10]	Holt JB, Miller BJ, Callaghan JJ, Clark CR, Willenborg MD, Noiseux NO. Minimizing blood transfusion in total hip and knee arthroplasty through a multimodal approach. J Arthroplasty. 2016; 31: 378–382.
[11]	Kamath AF, Pagnano MW. Blood management for patients undergoing total joint arthroplasty. JBJS Rev. doi: 10.2106/JBJS.RVW.M.00046. Published online Decmber 3, 2013.
[12]	Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012; 130: S7–S11.
[13]	Blanie A, Bellamy L, Rhayem Y, et al. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thrombosis Research 2013; 131: e6–e11.
[14]	L. Klenerman, R. Chakrabarti, I. Mackie, M. Brozovic, and Y. Stirling, “Changes in hæmostatic system after application of a tourniquet,” The Lancet, vol. 309, no. 8019, pp. 970–972, 1977.
[15]	Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014; 54 (5): 1389–1405. quiz 1388. [PubMed] [Google Scholar]
[16]	Steinmetz J, Sørensen AM, Henriksen HH, et al. Pilot Randomized trial of Fibrinogen in Trauma Haemorrhage (PRooF-iTH): study protocol for a randomized controlled trial. Trials. 2016; 17 (1): 327–327.
[17]	Rahe-Meyer N, Solomon C, Winterhalter M, et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009; 138 (3): 694–702d loss with plasma-poor red cell concentrates. Anesth Analg. 1995; 8 1.
[18]	Beyerle A, Nolte MW, Solomon C, Herzog E, Dickneite G. Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals. Toxicol Appl Pharmacol. 2014; 280 (1): 70–77.
[19]	Goel R, Buckley P, Sterbis E, Parvizi J. Patients with infected Total hip arthroplasty undergoing 2-stage exchange arthroplasty experience massive blood loss. J Arthroplast. 2018; 33 (11): 3547–50.
[20]	Fromme GA, MaccKenzie RA, Gould AB Jr., Lund BA, Offord KP. Controlled hypotention for orthognathic surgery. Anesthesia Analgesia 1986; 65: 683-6.
[21]	Pachore, J. A., Shah, V. I., Upadhyay, S., Shah, K., Sheth, A., & Kshatriya, A. (2019). The use of tranexamic acid to reduce blood loss in uncemented total hip arthroplasty for avascular necrosis of femoral head: A prospective blinded randomized controlled study. Arthroplasty, 1 (1). https://doi.org/10.1186/s42836-019-0012-6.
[22]	Najafi A, Moharari RS, Orandi AA, et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trial study. Acta Medica Iranica. 2014; 52 (11): 804–810.
[23]	Bardia Barimani, Philippe Moisan, Carlos Santagauida, Michael Weber Therapeutic Application of fibrinogen in Spine Surgery: A Review Article I J of Spine Surgery June 2021, 15 (3) 549-561.
[24]	2M. Soleimani, N. Masoumi, N. Nooraei, A. Lashay, M. R. Safarinejad JThromb Haemost November 2016, 15 (2) 255-262.
[25]	Baskaran D, Rahman S, Salanasi Y, Foroghi S, Berber O, George M. Effect of Tranexamic acid use on blood loss and thrombo embolic risk in hip fracture surgery: Systematic review and meta-analysis. Hip Int.2018 Jan; 28 (1): 3-10. doi: 10.5301/hipint.5000556.PMID:28983887.
[26]	Carlos Eduardo Pinz’on, K. M. Ve’lez, Can’as. D. M. Di’az Quijano. E fficiency of Tranexamic acid in peri operative blood loss in hip arthroplasty: A Systematic literature review and meta-analysis. Revista Espanola de Anestesiologi’ay Reanimacio’n (English Edition) 62 (5) DOI: 10.1016/J.redare.2015.03.001.
[27]	Z.-G. Yang, W.-P. Chen, and L.-D. Wu, “Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis,” The Journal of Bone and Joint Surgery-American Volume, vol. 94, no. 13, pp. 1153–1159, 2012.
[28]	Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; 1: CD001886.
[29]	Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, et al. The efficacy of tranexamic acid in Total hip arthroplasty: a network meta-analysis. J Arthroplast. 2018; 33 (10): 3083–9e4.
[30]	Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116 (22): 2544-52.
[31]	Dickneite G, Pragst I, Joch C, et al. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009; 20 (7): 535-40.
[32]	Manco-Johnson MJ, Dimichele D, Castaman G, et al. Fibrinogen Concentrate Study Group: Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009; 7 (12): 2064-9.
[33]	Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 2006; 60 (6 Suppl): S51-8.
[34]	Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67 (3): 365-8.
[35]	Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing. J Thromb Haemost 2009; 7 (5): 795-802.
[36]	Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indica tions. Drugs 1999; 57: 1005–1032.
[37]	Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res 2013; 471: 150–154.
[38]	Zufferey PJ, Miquet M, Quenet S, et al. Tranexamic acid in hip-fracture surgery (THIF) study. Tranexamic acid in hip frac ture surgery: a randomized controlled trial. Br J Anaesth. 2010; 104 (1): 23-30.
[39]	Emara WM, Moez KK, Elkhouly AH. Topical versus intravenous tranexamic acid as a blood conservation intervention for re duction of post-operative bleeding in hemiarthroplasty. Anesth Essays Res. 2014; 8 (1): 48-53.
[40]	Ekbäck G, Axelsson K, Ryttberg L, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000; 91: 1124–1130.
[41]	Imai N, Dohmae Y, Suda K, et al. Tranexamic acid for reduction of blood loss during total hip arthroplasty. J Arthroplasty 2012; 27: 1838–1843.
[42]	Walsh M, Preston C, Bong M, Patel V, Di Cesare PE. Relative risk factors for requirement of blood transfusion after total hip arthroplasty. J Arthroplasty 2007; 22: 1162–1167.

Cite This Article

Plain Text BibTeX RIS

APA Style

Jehan Mohammad Ezzat Hamed, Rabab Mohamed Mohamed. (2022). A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA). International Journal of Anesthesia and Clinical Medicine, 10(1), 16-23. https://doi.org/10.11648/j.ijacm.20221001.13

Copy | Download

ACS Style

Jehan Mohammad Ezzat Hamed; Rabab Mohamed Mohamed. A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA). Int. J. Anesth. Clin. Med. 2022, 10(1), 16-23. doi: 10.11648/j.ijacm.20221001.13

Copy | Download

AMA Style

Jehan Mohammad Ezzat Hamed, Rabab Mohamed Mohamed. A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA). Int J Anesth Clin Med. 2022;10(1):16-23. doi: 10.11648/j.ijacm.20221001.13

Copy | Download

@article{10.11648/j.ijacm.20221001.13,
  author = {Jehan Mohammad Ezzat Hamed and Rabab Mohamed Mohamed},
  title = {A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA)},
  journal = {International Journal of Anesthesia and Clinical Medicine},
  volume = {10},
  number = {1},
  pages = {16-23},
  doi = {10.11648/j.ijacm.20221001.13},
  url = {https://doi.org/10.11648/j.ijacm.20221001.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijacm.20221001.13},
  abstract = {Total hip arthroplasty (THA) faces the hazard of surgical blood loss and significant invisible blood loss due to bleeding into tissue and hemolysis. Tranexamic acid (TXA) and fibrinogen are important agents among a diversity of intraoperative blood management protocols. During the coagulation cascade, thrombin enhances fibrinogen and hastens fibrin polymerization forming an intense network important in clot formation. Our study included sixty male patients that were randomized into two groups; patients receiving 15 mg/kg TXA given as a single slow intravenous bolus injection 15 minutes before incision were placed in (group 1). Patients receiving 30 mg/kg fibrinogen concentrate administered post induction of general anesthesia were placed in (group 2). Intraoperative (IO) mean heart rate (HR) and mean arterial pressure (MAP) showed no significant differences. There was a significant decrease in IO blood loss in fibrinogen (723.03. ± 117.69) group compared to TXA (879.30 ± 168.54) (p=0.001), with significant (P=0.010) differences in the amount of transfused packed RBCs (IQR:1-2). Field visibility also improved significantly (p=0. 017) in fibrinogen group. The amounts of Lactated Ringer’s (LR) solution infused during surgery were not significantly different while a significant (p=0.037) decrease in the additional amount of hydroxyethyl starch (HES) solution infused in patients with fibrinogen (211.87 ± 32.30) over TXA (250.63 ± 43.65) was noted. In conclusion, administration of fibrinogen concentrate before procedure in patients undergoing THA reduces blood loss. Consequently, this therapeutic process has the potential to change the treatment model for perioperative hemorrhage in patients with potentially life-threatening coagulopathy.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA)
AU  - Jehan Mohammad Ezzat Hamed
AU  - Rabab Mohamed Mohamed
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.ijacm.20221001.13
DO  - 10.11648/j.ijacm.20221001.13
T2  - International Journal of Anesthesia and Clinical Medicine
JF  - International Journal of Anesthesia and Clinical Medicine
JO  - International Journal of Anesthesia and Clinical Medicine
SP  - 16
EP  - 23
PB  - Science Publishing Group
SN  - 2997-2698
UR  - https://doi.org/10.11648/j.ijacm.20221001.13
AB  - Total hip arthroplasty (THA) faces the hazard of surgical blood loss and significant invisible blood loss due to bleeding into tissue and hemolysis. Tranexamic acid (TXA) and fibrinogen are important agents among a diversity of intraoperative blood management protocols. During the coagulation cascade, thrombin enhances fibrinogen and hastens fibrin polymerization forming an intense network important in clot formation. Our study included sixty male patients that were randomized into two groups; patients receiving 15 mg/kg TXA given as a single slow intravenous bolus injection 15 minutes before incision were placed in (group 1). Patients receiving 30 mg/kg fibrinogen concentrate administered post induction of general anesthesia were placed in (group 2). Intraoperative (IO) mean heart rate (HR) and mean arterial pressure (MAP) showed no significant differences. There was a significant decrease in IO blood loss in fibrinogen (723.03. ± 117.69) group compared to TXA (879.30 ± 168.54) (p=0.001), with significant (P=0.010) differences in the amount of transfused packed RBCs (IQR:1-2). Field visibility also improved significantly (p=0. 017) in fibrinogen group. The amounts of Lactated Ringer’s (LR) solution infused during surgery were not significantly different while a significant (p=0.037) decrease in the additional amount of hydroxyethyl starch (HES) solution infused in patients with fibrinogen (211.87 ± 32.30) over TXA (250.63 ± 43.65) was noted. In conclusion, administration of fibrinogen concentrate before procedure in patients undergoing THA reduces blood loss. Consequently, this therapeutic process has the potential to change the treatment model for perioperative hemorrhage in patients with potentially life-threatening coagulopathy.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Jehan Mohammad Ezzat Hamed

Faculty of Medicine, Tanta University, Tanta, Egypt
Rabab Mohamed Mohamed

Faculty of Medicine, Tanta University, Tanta, Egypt

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Jehan Mohammad Ezzat Hamed, Rabab Mohamed Mohamed. (2022). A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA). International Journal of Anesthesia and Clinical Medicine, 10(1), 16-23. https://doi.org/10.11648/j.ijacm.20221001.13

Copy | Download

ACS Style

Jehan Mohammad Ezzat Hamed; Rabab Mohamed Mohamed. A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA). Int. J. Anesth. Clin. Med. 2022, 10(1), 16-23. doi: 10.11648/j.ijacm.20221001.13

Copy | Download

AMA Style

Jehan Mohammad Ezzat Hamed, Rabab Mohamed Mohamed. A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA). Int J Anesth Clin Med. 2022;10(1):16-23. doi: 10.11648/j.ijacm.20221001.13

Copy | Download

@article{10.11648/j.ijacm.20221001.13,
  author = {Jehan Mohammad Ezzat Hamed and Rabab Mohamed Mohamed},
  title = {A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA)},
  journal = {International Journal of Anesthesia and Clinical Medicine},
  volume = {10},
  number = {1},
  pages = {16-23},
  doi = {10.11648/j.ijacm.20221001.13},
  url = {https://doi.org/10.11648/j.ijacm.20221001.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijacm.20221001.13},
  abstract = {Total hip arthroplasty (THA) faces the hazard of surgical blood loss and significant invisible blood loss due to bleeding into tissue and hemolysis. Tranexamic acid (TXA) and fibrinogen are important agents among a diversity of intraoperative blood management protocols. During the coagulation cascade, thrombin enhances fibrinogen and hastens fibrin polymerization forming an intense network important in clot formation. Our study included sixty male patients that were randomized into two groups; patients receiving 15 mg/kg TXA given as a single slow intravenous bolus injection 15 minutes before incision were placed in (group 1). Patients receiving 30 mg/kg fibrinogen concentrate administered post induction of general anesthesia were placed in (group 2). Intraoperative (IO) mean heart rate (HR) and mean arterial pressure (MAP) showed no significant differences. There was a significant decrease in IO blood loss in fibrinogen (723.03. ± 117.69) group compared to TXA (879.30 ± 168.54) (p=0.001), with significant (P=0.010) differences in the amount of transfused packed RBCs (IQR:1-2). Field visibility also improved significantly (p=0. 017) in fibrinogen group. The amounts of Lactated Ringer’s (LR) solution infused during surgery were not significantly different while a significant (p=0.037) decrease in the additional amount of hydroxyethyl starch (HES) solution infused in patients with fibrinogen (211.87 ± 32.30) over TXA (250.63 ± 43.65) was noted. In conclusion, administration of fibrinogen concentrate before procedure in patients undergoing THA reduces blood loss. Consequently, this therapeutic process has the potential to change the treatment model for perioperative hemorrhage in patients with potentially life-threatening coagulopathy.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - A Comparative Study Between Tranexamic Acid (TXA) and Fibrinongen Concentrate in Bleeding Control of Total Hip Arthroplasty (THA)
AU  - Jehan Mohammad Ezzat Hamed
AU  - Rabab Mohamed Mohamed
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.ijacm.20221001.13
DO  - 10.11648/j.ijacm.20221001.13
T2  - International Journal of Anesthesia and Clinical Medicine
JF  - International Journal of Anesthesia and Clinical Medicine
JO  - International Journal of Anesthesia and Clinical Medicine
SP  - 16
EP  - 23
PB  - Science Publishing Group
SN  - 2997-2698
UR  - https://doi.org/10.11648/j.ijacm.20221001.13
AB  - Total hip arthroplasty (THA) faces the hazard of surgical blood loss and significant invisible blood loss due to bleeding into tissue and hemolysis. Tranexamic acid (TXA) and fibrinogen are important agents among a diversity of intraoperative blood management protocols. During the coagulation cascade, thrombin enhances fibrinogen and hastens fibrin polymerization forming an intense network important in clot formation. Our study included sixty male patients that were randomized into two groups; patients receiving 15 mg/kg TXA given as a single slow intravenous bolus injection 15 minutes before incision were placed in (group 1). Patients receiving 30 mg/kg fibrinogen concentrate administered post induction of general anesthesia were placed in (group 2). Intraoperative (IO) mean heart rate (HR) and mean arterial pressure (MAP) showed no significant differences. There was a significant decrease in IO blood loss in fibrinogen (723.03. ± 117.69) group compared to TXA (879.30 ± 168.54) (p=0.001), with significant (P=0.010) differences in the amount of transfused packed RBCs (IQR:1-2). Field visibility also improved significantly (p=0. 017) in fibrinogen group. The amounts of Lactated Ringer’s (LR) solution infused during surgery were not significantly different while a significant (p=0.037) decrease in the additional amount of hydroxyethyl starch (HES) solution infused in patients with fibrinogen (211.87 ± 32.30) over TXA (250.63 ± 43.65) was noted. In conclusion, administration of fibrinogen concentrate before procedure in patients undergoing THA reduces blood loss. Consequently, this therapeutic process has the potential to change the treatment model for perioperative hemorrhage in patients with potentially life-threatening coagulopathy.
VL  - 10
IS  - 1
ER  -

Copy | Download